Differentiated Cells

NurOwn is our autologous, adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells (MSC) into specialized, neuron-supporting cells.

 

These neuron-supporting cells (known as “MSC-NTF” cells) secrete neurotrophic, or nerve-growth, factors for PROTECTION of existing motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT of nerve-muscle interaction.

 

The ability to differentiate mesenchymal stem cells into MSC-NTF cells, and confirmation of their activity and potency before transplantation, makes NurOwn a first-of-its-kind approach for treating neurodegenerative diseases.

 

 images/34.jpg

Autologous (“Self-transplantation”)

The NurOwn approach is autologous, or self-transplanted, using the patient’s own stem cells. It has a high safety profile, with no risk of rejection and no need for treatment with immunosuppressive agents, which can cause severe and/or long-term side effects. In addition, it is free of controversy associated with the use of embryonic stem cells in some countries.

The NurOwn Transplantation Process

 images/NurOwn_diagram_JPEG.jpg

A sample of the patient’s bone marrow is harvested, and the Mesenchymal Stem Cells (MSCs) are isolated.

The MSCs are then expanded and induced to differentiate into MSC-NTF cells.

The cells are then transplanted back into the patient - into the spinal cord or muscles.

The NurOwn technology is based on the scientific achievements of Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center in Israel and Scientific Committee member of the Michael J. Fox Foundation for Parkinson's Research, and Professor Daniel Offen, Head of the Neuroscience Laboratory, Felsenstein Medical Research Center (FMRC) at Tel Aviv University.